Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets
Andreas H. Kottman, PhD, Columbia University
Polo-like kinases as therapeutic targets for Parkinson's disease
Hilal A. Lashuel, PhD, and Patrick Aebischer, MD, Ecole Polytechnique Federale de Lausanne (Switzerland) and Deniz Kirik, MD, PhD, Lund University (Sweden)
Validation of cyclophilin D, a protein involved in the mitochondrial permeability transition, as a target for Parkinson's disease therapy
Mathieu Lesort, PhD, University of Alabama at Birmingham
The therapeutic role of CMA-MEF2D in the survival of dopamine neurons
Zixu Mao, PhD, Emory University
SHP-2 phosphatase: A new pharmacological target for Parkinson's disease?
Maria-Cristina Missale, PhD, University of Brescia (Italy)
Validation of Nurr1 as a Drug Target for the Treatment of PD
Demetrios K. Vassilatis, PhD, Foundation for Biomedical Research of the Academy of Athens, Greece
About The Michael J. Fox Foundation
Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded over $145 million in research to date.